CGENHealthcare · BiotechnologyThe 5 Wall Street analysts covering Compugen Ltd. hold a median 12-month price target of $4 — +100.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Compugen Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CGEN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +100.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 May 2026 | Leerink Partners | Maintains | Outperform | $13 → $5.00 |
| 7 Apr 2026 | Lake Street | Initiates | Buy | — |
| 7 Jan 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 21 May 2024 | Truist Securities | Maintains | Buy | — |
| 8 Mar 2024 | Truist Securities | Maintains | Buy | — |
| 19 Dec 2023 | Stifel | Maintains | Buy | — |
| 23 Aug 2023 | Truist Securities | Reiterates | Buy | — |
| 7 Aug 2023 | EF Hutton | Reiterates | Buy | — |
| 6 June 2023 | EF Hutton | Reiterates | Buy | — |
| 26 May 2023 | EF Hutton | Reiterates | Buy | — |
| 24 May 2023 | EF Hutton | Reiterates | Buy | — |
| 16 May 2023 | Oppenheimer | Maintains | Outperform | — |
| 28 Feb 2023 | Oppenheimer | Reiterates | Outperform | — |
| 8 Feb 2023 | Jefferies | Downgrade | Underperform | — |
| 5 Jan 2023 | EF Hutton | Initiates | Buy | — |
| 15 Nov 2022 | Oppenheimer | Maintains | Outperform | — |
| 23 Aug 2022 | Truist Securities | Maintains | Buy | — |
| 8 Aug 2022 | JMP Securities | Maintains | Market Outperform | — |
| 8 Aug 2022 | Oppenheimer | Maintains | Outperform | — |
| 5 Aug 2022 | Jefferies | Downgrade | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CGEN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Compugen Ltd. returned −5.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 66% of US stocks
Cheaper than 45% of US stocks
Cheaper than 41% of US stocks
Cheaper than 57% of US stocks
Higher than 93% of US stocks
Higher than 84% of US stocks
Higher than 4% of US stocks
Higher than 9% of US stocks
Higher than 96% of US stocks
Higher than 93% of US stocks
Higher than 97% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Compugen Ltd. has a market value of $187.6M and an enterprise value of $65.3M.
Revenue in the twelve months to 30 June 2026: $74.0M. The latest quarter grew 107.0% year on year.
Net income over the same four quarters: $35.2M, a 47.6% net margin.
Diluted earnings per share, trailing twelve months: $0.38.
Trailing P/E: 5.2×; forward P/E: −5.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Compugen Ltd. employs 75 people — $987K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Compugen Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Compugen announced that its management will participate in a fireside chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference.
Why it matters — The announcement gives CGEN watchers information about a management appearance at a conference focused on AI-based drug discovery and development.
Compugen outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and announced an expansion of its AI-powered discovery platform into tumor-associated antigen research during a company update event.
Why it matters — This provides CGEN watchers with updates on the company's ovarian cancer clinical program and a broadening of its AI drug-discovery capabilities into a new target area.
Compugen Ltd. discussed its COM701 candidate in ovarian cancer, provided a preview of the MAIA trial, and detailed advancements in its UNIGEN platform during a company transcript covered by Seeking Alpha.
Why it matters — CGEN watchers would gain insight into the company's clinical pipeline and platform developments that could shape its future.
Compugen Ltd. announced it will host a virtual Key Opinion Leader (KOL) event on October 5, 2026, focusing on its COM701 candidate in ovarian cancer and providing an update on its Unigen™ platform. The event will be held by the Israeli biotech company.
Why it matters — CGEN watchers would be interested as the event offers a closer look at the company's ovarian cancer candidate COM701 and the progress of its Unigen™ platform.
Compugen Ltd., based in Holon, Israel, announced that it will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 8, 2026. The event provides an opportunity for the company's leadership to present to investors.
Why it matters — This participation offers Compugen visibility and a platform to communicate its progress and strategy to the investment community at a major industry conference.
The 5 Wall Street analysts covering Compugen Ltd. have a median 12-month price target of $4, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Compugen Ltd., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Compugen Ltd. 86 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Compugen Ltd. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +100.0% from the last close, and Ticker Nerd's factor model ranks Compugen Ltd. 86 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Compugen Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.
Compugen Ltd. returned -5.2% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapy and autoimmune diseases.
The most recent item we track (PRNewsWire, 6 Oct 2026): "Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference". Compugen announced that its management will participate in a fireside chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference.
Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapy and autoimmune diseases. Compugen Ltd. uses its AI- and machine learning-powered Unigen platform to identify novel drug targets, validate biological pathways, and advance therapeutic and diagnostic biomarker candidates. Its current work centers on developing antibodies and other biologic product candidates for oncology and immune-related conditions, with programs designed to address unmet needs in solid tumors and inflammatory diseases. The company operates across Israel, the United States, and Europe, supporting research, development, and commercial collaboration activities. Headquartered in Holon, Israel, Compugen Ltd. plays a role in the biotechnology market as a platform-driven company that combines computational discovery with experimental development to build differentiated drug candidates.
CEO Dr. Eran Ophir Ph.D. · 75 employees · Israel · https://cgen.com
